First AD

Second AD

SGLT2 Inhibitors, RAAS Inhibitors, and GLP-1 Receptor Agonists

How do SGLT2 inhibitors, RAAS inhibitors, and GLP-1 receptor agonists differ in their treatment of CKD in patients with type 2 diabetes?

Discuss your approach for patients who experience hyperkalemia during treatment. What strategies do you use to help them get back on their treatment course?

Enhancing CKD Care in Type 2 Diabetes: Bridging Gaps in Diagnosis, Treatment, and Patient Outcomes

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

SGLT2 inhibitors, RAAS inhibitors, and GLP-1 receptor agonists each offer distinct mechanisms for managing chronic kidney disease (CKD) in type 2 diabetes patients. SGLT2 inhibitors primarily reduce glucose reabsorption in the kidneys, offering renal protection and cardiovascular benefits. RAAS inhibitors target the renin-angiotensin-aldosterone system, reducing blood pressure and proteinuria, thus slowing CKD progression. GLP-1 receptor agonists enhance insulin secretion and provide cardiovascular protection. For hyperkalemia management, strategies include dietary potassium restriction, use of potassium binders, and adjusting medications. These interventions aim to maintain treatment efficacy while mitigating hyperkalemia risks.

Panelists discuss how SGLT2 inhibitors, RAAS inhibitors, and GLP-1 receptor agonists differ in their treatment of chronic kidney disease (CKD) in patients with type 2 diabetes, along with strategies for managing hyperkalemia in patients to help them resume their treatment course.

SGLT2 inhibitors, RAAS inhibitors, nsMRAs, & GLP-1 receptor Agonists